Published in Proc Natl Acad Sci U S A on February 19, 2004
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A (2007) 2.52
Mutational spectra of human cancer. Hum Genet (2009) 2.26
Regulation of female reproduction by p53 and its family members. FASEB J (2011) 1.08
Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat Res (2013) 1.02
Modelling mutational landscapes of human cancers in vitro. Sci Rep (2014) 0.99
Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J Biol Chem (2010) 0.97
Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. FASEB J (2010) 0.94
p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy. Mutat Res (2009) 0.93
Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes Dev (2008) 0.90
TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts. Mutat Res (2015) 0.89
Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells. Nat Protoc (2012) 0.85
The genome as a record of environmental exposure. Mutagenesis (2015) 0.85
How the environment shapes cancer genomes. Curr Opin Oncol (2015) 0.80
A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. J Biol Chem (2013) 0.79
Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts. Toxicol In Vitro (2014) 0.79
Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome. Mol Carcinog (2010) 0.78
Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter. Mol Carcinog (2015) 0.77
Contribution of biotransformation enzymes to the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions, difficult answers. Interdiscip Toxicol (2008) 0.77
Base changes in tumour DNA have the power to reveal the causes and evolution of cancer. Oncogene (2016) 0.75
Nutlin-3a selects for cells harbouring TP53 mutations. Int J Cancer (2016) 0.75
Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol (2016) 0.75
Surfing the p53 network. Nature (2000) 35.36
p53 mutations in human cancers. Science (1991) 31.96
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N Engl J Med (2000) 8.02
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A (1991) 6.42
Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64
Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene (1997) 5.64
Modelling the molecular circuitry of cancer. Nat Rev Cancer (2002) 5.43
p53 and human cancer: the first ten thousand mutations. Adv Cancer Res (2000) 4.71
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev (1991) 4.01
Subpathways of nucleotide excision repair and their regulation. Oncogene (2002) 2.92
Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A (1993) 2.89
Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis (2001) 2.66
Cytochrome P450 and the individuality of species. Arch Biochem Biophys (1999) 2.42
Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet (1993) 2.40
Sunlight and the onset of skin cancer. Trends Genet (1997) 2.33
Carcinogens induce targeted mutations in Escherichia coli. Cell (1982) 2.12
Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med (2001) 2.10
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A (1999) 2.08
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis (2002) 1.90
Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci U S A (1999) 1.73
Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res (1996) 1.65
Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res (1998) 1.64
Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene (2001) 1.57
From gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer Res (1991) 1.53
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A (2003) 1.41
Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch Biochem Biophys (2003) 1.37
Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. Proc Natl Acad Sci U S A (2002) 1.20
Sunlight induces pyrimidine dimers preferentially at 5-methylcytosine bases. Cancer Res (1997) 1.19
Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res (2001) 1.17
The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. Oncogene (1993) 1.15
Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene (2003) 1.07
32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis (1997) 1.05
Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res (1990) 1.02
Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation. Chem Res Toxicol (2002) 1.01
DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis (2004) 0.99
Fidelity of uracil-initiated base excision DNA repair in DNA polymerase beta-proficient and -deficient mouse embryonic fibroblast cell extracts. J Biol Chem (2001) 0.98
Simulated sunlight and benzo[a]pyrene diol epoxide induced mutagenesis in the human p53 gene evaluated by the yeast functional assay: lack of correspondence to tumor mutation spectra. Carcinogenesis (2003) 0.96
Detection and classification of mutagens: a set of base-specific Salmonella tester strains. Proc Natl Acad Sci U S A (1994) 0.96
Use of a novel real-time quantitative reverse transcription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver. Drug Metab Dispos (2000) 0.93
Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) with induced adipocyte differentiation in mouse embryonic fibroblasts (MEFs) involves tyrosine kinase c-Src. Biochem Pharmacol (2003) 0.92
Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse). Mutat Res (2002) 0.92
UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res (2001) 0.91
Mining databases for cytochrome P450 genes. Methods Enzymol (2002) 0.91
Mouse models with modified p53 sequences to study cancer and ageing. Cell Death Differ (2003) 0.86
UV-induced mutagenesis of human p53 in a vector replicated in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1997) 0.84
In vitro mutational spectrum of aflatoxin B1 in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res (1994) 0.83
The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts. Mutat Res (2000) 0.82
Induction of mutations in transgenic animal models: BigBlue and Muta Mouse. IARC Sci Publ (1999) 0.78
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med (2005) 4.06
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol (2007) 3.86
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform. Cell Cycle (2011) 2.79
Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med (2004) 2.23
Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci (2010) 2.03
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol (2002) 1.96
Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis (2002) 1.90
Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. Proc Natl Acad Sci U S A (2012) 1.67
The rational design of nitric oxide selectivity in single-walled carbon nanotube near-infrared fluorescence sensors for biological detection. Nat Chem (2009) 1.64
TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer (2009) 1.52
Nitric oxide as a modulator of apoptosis. Cancer Lett (2004) 1.48
Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis (2007) 1.39
High-accuracy amplification of nanogram total RNA amounts for gene profiling. Genomics (2004) 1.35
Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proc Natl Acad Sci U S A (2013) 1.29
Nitric oxide in cancer and chemoprevention. Free Radic Biol Med (2003) 1.29
The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med (2013) 1.23
The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol (2011) 1.20
Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle (2006) 1.15
How to become immortal: let MEFs count the ways. Aging (Albany NY) (2010) 1.14
Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res (2007) 1.12
Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer (2005) 1.08
Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells. Proc Natl Acad Sci U S A (2009) 1.08
Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res (2004) 1.06
In vivo biosensing via tissue-localizable near-infrared-fluorescent single-walled carbon nanotubes. Nat Nanotechnol (2013) 1.06
Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53. Proc Natl Acad Sci U S A (2002) 1.06
Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids Res (2012) 1.05
MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis (2006) 1.04
Thresholds of nitric oxide-mediated toxicity in human lymphoblastoid cells. Chem Res Toxicol (2003) 1.03
Modulation of CYP1A1-mediated oxidation of carcinogenic azo dye Sudan I and its binding to DNA by cytochrome b5. Neuro Endocrinol Lett (2006) 1.03
p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res (2005) 1.01
Genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells exposed to peroxynitrite generated from SIN-1. Chem Res Toxicol (2002) 1.00
Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer (2002) 0.99
DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis (2004) 0.99
Detection and quantification of 4-ABP adducts in DNA from bladder cancer patients. Carcinogenesis (2006) 0.98
Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J Biol Chem (2010) 0.97
Threshold effects of nitric oxide-induced toxicity and cellular responses in wild-type and p53-null human lymphoblastoid cells. Chem Res Toxicol (2006) 0.97
Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. Proc Natl Acad Sci U S A (2013) 0.97
Identification of three major DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in rat lung at the C8 and N2 position of guanine and at the N6 position of adenine. Int J Cancer (2006) 0.97
Aflatoxin B1-DNA adduct formation and mutagenicity in livers of neonatal male and female B6C3F1 mice. Toxicol Sci (2011) 0.96
Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2006) 0.96
Mutagenic potency of Helicobacter pylori in the gastric mucosa of mice is determined by sex and duration of infection. Proc Natl Acad Sci U S A (2010) 0.96
Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer (2014) 0.96
Mechanism-based triarylphosphine-ester probes for capture of endogenous RSNOs. J Am Chem Soc (2013) 0.96
Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer (2004) 0.96
Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle (2011) 0.93
Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis (2003) 0.93
Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase. Carcinogenesis (2002) 0.93
The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen (2011) 0.93
The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences. Mutagenesis (2008) 0.93
Aristolochic acid nephropathy revisited: a place for innate and adaptive immunity? Histopathology (2010) 0.92
Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol Sci (2011) 0.92
Rosuvastatin: an independent analysis of risks and benefits. MedGenMed (2006) 0.91
Analysis of CREM-dependent gene expression during mouse spermatogenesis. Mol Cell Endocrinol (2003) 0.91
Mutagenicity and DNA adduct formation of PAH, nitro-PAH, and oxy-PAH fractions of atmospheric particulate matter from São Paulo, Brazil. Mutat Res (2008) 0.90
DNA adducts and mutagenic specificity of the ubiquitous environmental pollutant 3-nitrobenzanthrone in Muta Mouse. Environ Mol Mutagen (2004) 0.90
Nitric oxide produced endogenously is responsible for hypoxia-induced HIF-1α stabilization in colon carcinoma cells. Chem Res Toxicol (2012) 0.90
Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin. Proc Natl Acad Sci U S A (2012) 0.90
Determination of genomic 5-hydroxymethyl-2'-deoxycytidine in human DNA by capillary electrophoresis with laser induced fluorescence. Epigenetics (2011) 0.90
Identification of a genotoxic mechanism for 2-nitroanisole carcinogenicity and of its carcinogenic potential for humans. Carcinogenesis (2004) 0.90
Biological role of glutathione in nitric oxide-induced toxicity in cell culture and animal models. Free Radic Biol Med (2005) 0.90
Activation of 3-nitrobenzanthrone and its metabolites by human acetyltransferases, sulfotransferases and cytochrome P450 expressed in Chinese hamster V79 cells. Int J Cancer (2003) 0.89
Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation. Anticancer Res (2009) 0.89
An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother (2007) 0.89
Oxidative detoxication of carcinogenic 2-nitroanisole by human, rat and rabbit cytochrome P450. Neuro Endocrinol Lett (2006) 0.89
Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis (2002) 0.89
DNA adduct formation by the ubiquitous environmental pollutant 3-nitrobenzanthrone and its metabolites in rats. Biochem Biophys Res Commun (2003) 0.89
Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer (2004) 0.89
Formation and persistence of DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in target and non-target organs after intratracheal instillation in rats. Carcinogenesis (2006) 0.88
Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab (2013) 0.88
Enzymes involved in the metabolism of the carcinogen 2-nitroanisole: evidence for its oxidative detoxication by human cytochromes P450. Chem Res Toxicol (2004) 0.88
Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol Lett (2008) 0.88
Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci (2011) 0.88
The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett (2005) 0.88
3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2. Chem Res Toxicol (2004) 0.88
Genotoxicity of 2,6- and 3,5-dimethylaniline in cultured mammalian cells: the role of reactive oxygen species. Toxicol Sci (2012) 0.87
Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice. Chem Res Toxicol (2011) 0.87
Monocyclic aromatic amines as potential human carcinogens: old is new again. Carcinogenesis (2009) 0.87
Induction of biotransformation enzymes by the carcinogenic air-pollutant 3-nitrobenzanthrone in liver, kidney and lung, after intra-tracheal instillation in rats. Mutat Res (2010) 0.87
The environmental pollutant and carcinogen 3-nitrobenzanthrone induces cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase in rat lung and kidney, thereby enhancing its own genotoxicity. Toxicology (2008) 0.86
Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency. Proc Natl Acad Sci U S A (2013) 0.86
Genotoxicity associated with NO production in macrophages and co-cultured target cells. Free Radic Biol Med (2002) 0.86
Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome p450 reductase. Cancer Res (2003) 0.86
Mutagenesis of the supF gene of pSP189 replicating in AD293 cells cocultivated with activated macrophages: roles of nitric oxide and reactive oxygen species. Chem Res Toxicol (2006) 0.86
Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer (2011) 0.86
Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett (2006) 0.86
3-Nitrobenzanthrone (3-NBA) induced micronucleus formation and DNA damage in human hepatoma (HepG2) cells. Toxicol Lett (2004) 0.85
Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells. Nat Protoc (2012) 0.85